A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration

Trial Profile

A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Registrational; Therapeutic Use
  • Acronyms TREND
  • Sponsors Novartis
  • Most Recent Events

    • 28 Apr 2016 This trial is completed in Belgium, Germany (end date: 19 Nov 2015), Slovakia (end date: 19 Nov 2015), Hungary (end date: 19 Nov 2015), Portugal (end date: 19 Nov 2015), Denmark (end date: 19 Nov 2015), Croatia (end date: 19 Nov 2015
    • 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top